Chromadex (CDXC) Issues Earnings Results, Misses Expectations By $0.04 EPS

Chromadex (NASDAQ:CDXC) announced its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04), Morningstar.com reports. Chromadex had a negative net margin of 82.82% and a negative return on equity of 65.33%. The company had revenue of $8.12 million for the quarter, compared to the consensus estimate of $9.00 million.

NASDAQ CDXC traded down $0.23 during trading on Thursday, reaching $3.47. 249,100 shares of the company’s stock traded hands, compared to its average volume of 338,966. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.65 and a current ratio of 4.24. The company has a market capitalization of $192.14 million, a price-to-earnings ratio of -9.91 and a beta of 1.35. Chromadex has a 12-month low of $3.19 and a 12-month high of $7.24.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp increased its position in Chromadex by 113.4% during the 2nd quarter. Northern Trust Corp now owns 119,300 shares of the company’s stock valued at $443,000 after purchasing an additional 63,398 shares during the period. Bank of New York Mellon Corp increased its position in Chromadex by 326.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 101,106 shares of the company’s stock valued at $375,000 after purchasing an additional 77,420 shares during the period. First Republic Investment Management Inc. purchased a new position in Chromadex during the 2nd quarter valued at about $995,000. BlackRock Inc. increased its position in Chromadex by 1,629.4% during the 2nd quarter. BlackRock Inc. now owns 1,884,616 shares of the company’s stock valued at $6,992,000 after purchasing an additional 1,775,638 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Chromadex during the 2nd quarter valued at about $193,000. 16.16% of the stock is currently owned by institutional investors and hedge funds.

CDXC has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Chromadex from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 24th. HC Wainwright set a $8.00 target price on shares of Chromadex and gave the company a “buy” rating in a research report on Monday, July 16th. Finally, BidaskClub downgraded shares of Chromadex from a “hold” rating to a “sell” rating in a research report on Friday, August 24th.

WARNING: “Chromadex (CDXC) Issues Earnings Results, Misses Expectations By $0.04 EPS” was reported by WKRB News and is owned by of WKRB News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.wkrb13.com/2018/11/09/chromadex-cdxc-issues-earnings-results-misses-expectations-by-0-04-eps.html.

About Chromadex

ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients.

See Also: Exchange-Traded Funds (ETFs)

Earnings History for Chromadex (NASDAQ:CDXC)

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply